Unexploited therapies in breast and prostate cancer: Blockade of the prolactin receptor

Trends in Endocrinology and Metabolism

Volumn 21, Issue 11, 2010, Pages 691-698

  Jacobson, Eric M ^a   Hugo, Eric R ^b   Tuttle, Traci R ^b   Papoian, Ruben ^a   Ben Jonathan, Nira ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CHORIONIC GONADOTROPIN; CISPLATIN; CYTOKINE RECEPTOR ANTAGONIST; DOXORUBICIN; GROWTH HORMONE; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACENTA LACTOGEN; PROLACTIN; PROLACTIN RECEPTOR; PROLACTIN RECEPTOR ANTAGONIST; STAT5 PROTEIN; UNCLASSIFIED DRUG;

BINDING SITE; BREAST CANCER; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER MODEL; DRUG STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; GROWTH HORMONE BLOOD LEVEL; HIGH THROUGHPUT SCREENING; HORMONE RESPONSE; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ACTIVITY RELATION; TROPHOBLAST; TUMOR GROWTH; VALIDATION STUDY;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HORMONE ANTAGONISTS; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; RECEPTORS, PROLACTIN; THERAPIES, INVESTIGATIONAL;

EID: 78049266294     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.08.004     Document Type: Review

References (79)

1. Lopez-Otin C., Diamandis E.P. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr. Rev. 1998, 19:365-396.
2. Ben-Jonathan N., et al. What can we learn from rodents about prolactin in humans?. Endocr. Rev. 2008, 29:1-41.
3. Svensson L.A., et al. Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor. J. Biol. Chem. 2008, 283:19085-19094.
4. Jomain J.B., et al. Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: X-ray structure of Del1-9-G129R-hPRL. J. Biol. Chem. 2007, 282:33118-33131.
5. Voorhees J.L., Brooks C.L. Obligate ordered binding of human lactogenic cytokines. J. Biol. Chem. 2010, 285:20022-20030.
6. Solomon G., et al. Large-scale preparation and in vitro characterization of biologically active human placental (20 and 22K) and pituitary (20K) growth hormones: placental growth hormones have no lactogenic activity in humans. Growth Horm. IGF Res. 2006, 16:297-307.
7. Broutin I., et al. Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2. J. Biol. Chem. 2010, 285:8422-8433.
8. Elkins P.A., et al. Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor. Nat. Struct. Biol. 2000, 7:808-815.
9. Tworoger S.S., et al. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J. Clin. Oncol. 2007, 25:1482-1488.
10. Tworoger S.S., Hankinson S.E. Prolactin and breast cancer etiology: an epidemiologic perspective. J. Mammary Gland Biol. Neoplasia 2008, 13:41-53.
11. Zinger M., et al. Prolactin expression and secretion by human breast glandular and adipose tissue explants. J. Clin. Endocrinol. Metab. 2003, 88:689-696.
12. Rose-Hellekant T.A., et al. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 2003, 22:4664-4674.
13. Wennbo H., et al. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J. Clin. Invest. 1997, 100:2744-2751.
14. Liby K., et al. Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res. Treat. 2003, 79:241-252.
15. Lapensee E.W., et al. Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis 2009, 30:1298-1304.
16. Lapensee E.W., Ben-Jonathan N. Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocr. Relat. Cancer 2010, 17:R91-R107.
17. Beck M.T., et al. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 2002, 21:5047-5055.
18. Lissoni P., et al. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines. Anticancer Res. 2002, 22:1131-1134.
19. Engel R.H., Kaklamani V.G. HER2-positive breast cancer: current and future treatment strategies. Drugs 2007, 67:1329-1341.
20. Yamauchi T., et al. Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J. Biol. Chem. 2000, 275:33937-33944.
21. Scotti M.L., et al. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res. Treat. 2008, 111:241-250.
22. Carver K.C., et al. Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells. J. Biol. Chem. 2010, 285:8003-8012.
23. Huang Y., et al. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene 2006, 25:7565-7576.
24. Chen Y., et al. Prolactin and estradiol utilize distinct mechanisms to increase serine-118 phosphorylation and decrease levels of estrogen receptor alpha in T47D breast cancer cells. Breast Cancer Res. Treat. 2010, 120:369-377.
25. Stattin P., et al. Plasma prolactin and prostate cancer risk: a prospective study. Int. J. Cancer 2001, 92:463-465.
26. Dillner K., et al. Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. Endocrinology 2003, 144:4955-4966.
27. Dagvadorj A., et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 2007, 148:3089-3101.
28. Xu X., et al. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice. Cancer Res. 2001, 61:6098-6104.
29. Hair W.M., et al. Prolactin receptor expression in human testis and accessory tissues: localization and function. Mol. Hum. Reprod. 2002, 8:606-611.
30. Sanati S., et al. Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod. Pathol. 2009, 22:1273-1279.
31. Li H., et al. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin. Cancer Res. 2005, 11:5863-5868.
32. Tan S.H., et al. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res. 2008, 68:236-248.
33. Gu L., et al. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr. Relat. Cancer 2010, 17:481-493.
34. Gu L., et al. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am. J. Pathol. 2010, 176:1959-1972.
35. Perry J.K., et al. The contribution of growth hormone to mammary neoplasia. J. Mammary Gland Biol. Neoplasia 2008, 13:131-145.
36. Fuhrman B., et al. Basal growth hormone concentrations in blood and the risk for prostate cancer: a case-control study. Prostate 2005, 64:109-115.
37. Chopin L.K., et al. Co-expression of GH and GHR isoforms in prostate cancer cell lines. Growth Horm. IGF Res. 2002, 12:126-136.
38. Gebre-Medhin M., et al. Growth hormone receptor is expressed in human breast cancer. Am. J. Pathol. 2001, 158:1217-1222.
39. Weiss-Messer E., et al. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol. Cell. Endocrinol. 2004, 220:109-123.
40. Kaulsay K.K., et al. The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 2001, 142:767-777.
41. Ferretti C., et al. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum. Reprod. Update 2007, 13:121-141.
42. Butler S.A., Iles R.K. Ectopic human chorionic gonadotropin beta secretion by epithelial tumors and human chorionic gonadotropin beta-induced apoptosis in Kaposi's sarcoma: is there a connection?. Clin. Cancer Res. 2003, 9:4666-4673.
43. Horne C.H., et al. Prognostic significance of inappropriate production of pregnancy proteins by breast cancers. Lancet 1976, 2:279-282.
44. Sheth N.A., et al. Ectopic production of human placental lactogen by human breast tumors. Cancer 1977, 39:1693-1699.
45. Lee A.K., et al. Tumor marker expression in breast carcinomas and relationship to prognosis. An immunohistochemical study. Am. J. Clin. Pathol. 1985, 84:687-696.
46. Polgar N., et al. Lysyl oxidase interacts with hormone placental lactogen and synergistically promotes breast epithelial cell proliferation and migration. J. Biol. Chem. 2007, 282:3262-3272.
47. Bonneterre J., et al. Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial. Eur. J. Cancer Clin. Oncol. 1988, 24:1851-1853.
48. Ben-Jonathan N., et al. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr. Rev. 1996, 17:639-669.
49. Chen W.Y., et al. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin. Cancer Res. 1999, 5:3583-3593.
50. Goffin V., et al. Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?. Nat. Clin. Pract. Endocrinol. Metab. 2006, 2:571-581.
51. Walker A.M. Therapeutic potential of S179D prolactin - from prostate cancer to angioproliferative disorders: the first selective prolactin receptor modulator. Expert Opin. Investig. Drugs 2006, 15:1257-1267.
52. Liu T., et al. Synthesis and screening of a cyclic peptide library: discovery of small-molecule ligands against human prolactin receptor. Bioorg. Med. Chem. 2009, 17:1026-1033.
53. Fox S., et al. High-throughput screening: update on practices and success. J. Biomol. Screen. 2006, 11:864-869.
54. Bleicher K.H., et al. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov. 2003, 2:369-378.
55. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
56. Neumann H., Neumann-Staubitz P. Synthetic biology approaches in drug discovery and pharmaceutical biotechnology. Appl. Microbiol. Biotechnol. 2010, 87:75-86.
57. Mobley D.L., Dill K.A. Binding of small-molecule ligands to proteins: 'what you see' is not always 'what you get'. Structure 2009, 17:489-498.
58. Fang F., et al. Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter. BMC Biotechnol. 2008, 8:11.
59. Osmond R.I., et al. Development of cell-based assays for cytokine receptor signaling, using an AlphaScreen SureFire assay format. Anal. Biochem. 2010, 403:94-101.
60. Bogorad R.L., et al. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14533-14538.
61. Courtillot C., et al. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. J. Clin. Endocrinol. Metab. 2010, 95:271-279.
62. Canbay E., et al. Could prolactin receptor gene polymorphism play a role in pathogenesis of breast carcinoma?. Curr. Med. Res. Opin. 2004, 20:533-540.
63. Fields K., et al. Detection of prolactin messenger RNA in mammary and other normal and neoplastic tissues by polymerase chain reaction. Lab. Invest. 1993, 68:354-360.
64. Shaw-Bruha C.M., et al. Expression of the prolactin gene in normal and neoplastic human breast tissues and human mammary cell lines: promoter usage and alternative mRNA splicing. Breast Cancer Res. Treat. 1997, 44:243-253.
65. Reynolds C., et al. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997, 138:5555-5560.
66. Mol J.A., et al. Expression of the gene encoding growth hormone in the human mammary gland. J. Clin. Endocrinol. Metab. 1995, 80:3094-3096.
67. Touraine P., et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J. Clin. Endocrinol. Metab. 1998, 83:667-674.
68. Mertani H.C., et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int. J. Cancer 1998, 79:202-211.
69. Bhatavdekar J.M., et al. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Ann. Surg. Oncol. 2000, 7:305-311.
70. Ormandy C.J., et al. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J. Clin. Endocrinol. Metab. 1997, 82:3692-3699.
71. Ginsburg E., Vonderhaar B.K. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res. 1995, 55:2591-2595.
72. Howell S.J., et al. Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res. 2008, 10:R68.
73. van G.E., Schalken J.A. Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. Mol. Cell. Endocrinol. 2002, 197:153-165.
74. Peirce S.K., et al. Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J. Endocrinol. 2001, 171:R1-R4.
75. Leav I., et al. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am. J. Pathol. 1999, 154:863-870.
76. Decouvelaere C., et al. Presence of the two growth hormone receptor messenger RNA isoforms in human breast cancer. Cell Growth Differ. 1995, 6:477-483.
77. Baudhuin A., et al. Transcription of the human prolactin gene in mammary cells. Ann. N. Y. Acad. Sci. 2002, 973:454-458.
78. Nevalainen M.T., et al. Prolactin and prolactin receptors are expressed and functioning in human prostate. J. Clin. Invest. 1997, 99:618-627.
79. Wang Y., et al. MMDB: annotating protein sequences with Entrez's 3D-structure database. Nucleic Acids Res. 2007, 35:D298-D300.